4174 Stock Overview
A clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
OBI Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$56.50 |
| 52 Week High | NT$92.90 |
| 52 Week Low | NT$55.00 |
| Beta | 0.99 |
| 1 Month Change | -1.91% |
| 3 Month Change | -15.92% |
| 1 Year Change | -15.67% |
| 3 Year Change | -47.69% |
| 5 Year Change | -57.03% |
| Change since IPO | -53.69% |
Recent News & Updates
Shareholder Returns
| 4174 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0.9% | -1.1% | 3.5% |
| 1Y | -15.7% | 14.5% | 28.0% |
Return vs Industry: 4174 underperformed the TW Biotechs industry which returned 14.5% over the past year.
Return vs Market: 4174 underperformed the TW Market which returned 28% over the past year.
Price Volatility
| 4174 volatility | |
|---|---|
| 4174 Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.9% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4174 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4174's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Heidi Wang | www.obipharma.com |
OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company’s pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of solid tumors; OBI-902 and OBI-904 that are in preclinical stage for the treatment of solid tumors; BsADC which is in discovery stage for the treatment of solid tumors. It also engages in investing and trading; and manufacture and wholesale of western pharmaceuticals, as well as research and development of biotechnology.
OBI Pharma, Inc. Fundamentals Summary
| 4174 fundamental statistics | |
|---|---|
| Market cap | NT$12.95b |
| Earnings (TTM) | -NT$2.11b |
| Revenue (TTM) | NT$69.55m |
186.2x
P/S Ratio-6.1x
P/E RatioIs 4174 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4174 income statement (TTM) | |
|---|---|
| Revenue | NT$69.55m |
| Cost of Revenue | NT$138.93m |
| Gross Profit | -NT$69.38m |
| Other Expenses | NT$2.04b |
| Earnings | -NT$2.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.19 |
| Gross Margin | -99.75% |
| Net Profit Margin | -3,028.89% |
| Debt/Equity Ratio | 1.7% |
How did 4174 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 10:51 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OBI Pharma, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pinghan Hsieh | Capital Securities Corporation |
| Li-chun Chang | Jih Sun Securities Investment Consulting Co., Ltd. |
| Yijun Chen | SinoPac Securities Investment Service |